The effectiveness of integrated treatment in patients with substance use disorders co-occurring with anxiety and/or depression--a group randomized trial

Linda E Wüsthoff, Helge Waal, Rolf W Gråwe, Linda E Wüsthoff, Helge Waal, Rolf W Gråwe

Abstract

Background: Integrated Treatment (IT) has proved effective in treating patients with Substance Use Disorders (SUD) co-occurring with severe Mental Disorders (MD), less is known about the effectiveness of IT for patients with SUD co-occurring with less severe MD.The aim of this study was to investigate the effectiveness of IT for patients with SUD co-occurring with anxiety and/or depression on the following parameters:1. The use of substances, as measured by the Alcohol Use Identification Test (AUDIT), the Drug Use Identification Test (DUDIT), and the Addiction Severity Index (EuropASI).2. The severity of psychiatric symptoms, as measured by the Symptom Check List 90 r (SCL 90R).3. The client's motivation for changing his/her substance use behaviour, as measured by the Substance Abuse Treatment Scale (SATSr).

Methods: This is a group randomized clinical trial comparing the effectiveness of IT to treatment as usual in Community Mental Health Centres (CMHCs). Five CMHCs were drawn to the Intervention Group (IG) and four CMHCs to the Control Group (CG). The allocation to treatment conditions was not blinded. New referrals were screened with the AUDIT and the DUDIT. Those who scored above the cut-off level of these instruments were assessed with the Structured Clinical Interview for DSM-IV 1 and 2. We included patients with anxiety and/or depression together with one or more SUDs.

Results: We included 55 patients in the IG and 21 in the CG. A linear multilevel model was used. Both groups reduced their alcohol and substance use during the trial, while there was no change in psychiatric symptoms in either group. However, the IG had a greater increase in motivation for substance use treatment after 12 months than had the CG with an estimate of 1.76, p = 0.043, CI95% (0.08; 3.44) (adjusted analyses). There were no adverse events.

Conclusions: Integrated treatment is effective in increasing the motivation for treatment amongst patients with anxiety and/or depression together with SUD in outpatient clinics.

Trial registration: ClinicalTrials.gov: NCT00447733.

Figures

Figure 1
Figure 1
Flowchart of participants. Flowchart of patients in the Intervention Group (IG) and the Control Group (CG) [54].

References

    1. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990;264:2511–2518. doi: 10.1001/jama.1990.03450190043026.
    1. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendlers KS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8–19. doi: 10.1001/archpsyc.1994.03950010008002.
    1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593–602. doi: 10.1001/archpsyc.62.6.593.
    1. Kessler RC, Nelson CB, McGonagle KA, Edlund MJ, Frank RG, Leaf PJ. The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. Am J Orthopsychiatry. 1996;66:17–31.
    1. Merikangas KR, Mehta RL, Molnar BE, Walters EE, Swendsen JD, Aguilar-Gaziola S, Bijl R, Borges G, Caraveo-Anduaga JJ, DeWit DJ, Kolody B, Vega WA, Wittchen HU, Kessler RC. Comorbidity of substance use disorders with mood and anxiety disorders: results of the International Consortium in Psychiatric Epidemiology. Addict Behav. 1998;23:893–907. doi: 10.1016/S0306-4603(98)00076-8.
    1. Crome IB. Substance misuse and psychiatric comorbidity: towards improved service provision. Drugs Educ Prev Policy. 1999;6:151–174. doi: 10.1080/09687639997115.
    1. Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. [References] Arch Gen Psychiatry. 2007;64:830–842. doi: 10.1001/archpsyc.64.7.830.
    1. Menezes PR, Johnson S, Thornicroft G, Marshall J. Drug and alcohol problems among individuals with severe mental illnesses in South London. Br J Psychiatry. 1996;168(5):612–619. doi: 10.1192/bjp.168.5.612.
    1. Bartels SJ, Teague GB, Drake RE, Clark RE. Substance abuse in schizophrenia: service utilization and costs. J Nerv Ment Dis. 1993;181:227–232. doi: 10.1097/00005053-199304000-00003.
    1. Baker KD, Lubman DI, Cosgrave EM, Killackey EJ, Yuen HP, Hides L, Baksheev GN, Buckby JA, Yung AR. Impact of co-occurring substance use on 6 month outcomes for young people seeking mental health treatment. Aust N Z J Psychiatry. 2007;41(11):896–902. doi: 10.1080/00048670701634986.
    1. Drake RE, Osher FC, Wallach MA. Alcohol use and abuse in schizophrenia. A prospective community study. J Nerv Ment Dis. 1989;177:408–414. doi: 10.1097/00005053-198907000-00004.
    1. Polcin DL. Issues in the treatment of dual diagnosis clients who have chronic mental-illness. Prof Psychol Res Pract. 1992;23:30–37.
    1. Compton WM III, Cottler LB, Jacobs JL, Ben-Abdallah A, Spitznagel EL. The role of psychiatric disorders in predicting drug dependence treatment outcomes. Am J Psychiatry. 2003;160:890–895. doi: 10.1176/appi.ajp.160.5.890.
    1. Weisner C, Matzger H, Kaskutas LA. How important is treatment? One-year outcomes of treated and untreated alcohol-dependent individuals. Addiction. 2003;98:901–911. doi: 10.1046/j.1360-0443.2003.00438.x.
    1. Sacks S, Chaple M, Sirikantraporn J, Sacks JY, Knickman J, Martinez J. Improving the capability to provide integrated mental health and substance abuse services in a state system of outpatient care. J Subst Abuse Treat. 2013;44:488–493. doi: 10.1016/j.jsat.2012.11.001.
    1. Green AI, Drake RE, Brunette MF, Noordsy DL. Schizophrenia and co-occurring substance use disorder. Am J Psychiatry. 2007;164:402–408. doi: 10.1176/appi.ajp.164.3.402.
    1. Mangrum LF, Spence RT, Lopez M. Integrated versus parallel treatment of co-occurring psychiatric and substance use disorders. J Subst Abuse Treat. 2006;30:79–84. doi: 10.1016/j.jsat.2005.10.004.
    1. Drake RE, Mueser KT, Clark RE, Wallach MA. The course, treatment, and outcome of substance disorder in persons with severe mental illness. Am J Orthopsychiatry. 1996;66:42–51.
    1. Minkoff K. An integrated treatment model for dual diagnosis of psychosis and addiction. Hosp Community Psychiatry. 1989;40:1031–1036.
    1. Minkoff K. Illinois Department of Human Services’ Office of Alcoholism and Substance Abuse, The Behavioral Health Recovery Management project. Peoria, IL: Chestnut Health Systems, Bloomington, IL; and the University of Chicago Center for Psychiatric Rehabilitation; 2001. Behavioral health recovery management service planning guidelines co-occurring psychiatric and substance use disorders; pp. 1–36. (An initiative of Fayette Companies).
    1. Miller WR. Motivational interviewing with problem drinkers. Behav Cogn Psychother. 1983;11:147–172. doi: 10.1017/S0141347300006583.
    1. Miller WR, Rollnick S. Motivational interviewing: Preparing people to Change Addictive Behavior. 72 Spring Street, New York, NY 10012: A Division of Guilford Publications, Inc, The Guilford Press; 1991.
    1. Miller WR, Rollnick S. Motivational interviewing: Preparing people for Change. 72 Spring Street, New York, NY 10012: A Division of Guilford Publications, Inc, The Guilford Press; 2002.
    1. Kendall PC. Cognitive-behavioral interventions: theory, research, and procedures. 111 Fifth Avenue, New York, New York 10003: Academic Press, Inc; 1979.
    1. Mueser KT, Noordsy DL, Drake RE, Fox L. Integrated Treatment for Dual Disorders: a guide to effective practice. 72 Spring Street, New York, NY 10012: A Division of Guilford Publications, Inc, The Guilford Press; 2003.
    1. Cleary M, Hunt GE, Matheson SL, Siegfried N, Walter G. Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev. 2008;1:CD001088.
    1. Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration (US) Substance abuse treatment for persons with co-occurring disorders. Treatment Improvement Protocol (TIP) Rockville (MD): Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration (US) Series, No. 42. SMA13-3992; 2008. Available from:
    1. Rush B. In: Best practices concurrent mental health and substance use disorders. Centre for Addiction and Mental Health, editor. Ottawa, Ontario, Canada: Publications Health Canada; 2002.
    1. Kirkhei I, Leiknes KA, Hammerstrom KT, Larun L, Bramnes JG, Grawe RW, Haugerud H, Helseth V, Landheim A, Lossius K, Waal H. Dual diagnoses - Severe Mental Illness and Substance Use Disorder. Part 2 - Effect of psychosocial interventions. No. 25, Oslo: Report from the Norwegian Knowledge Centre for the Health Services Systematic review; 2008.
    1. Wüsthoff LE, Waal H, Gråwe RW. When Research Meets Reality; Lessons Learned From a Pragmatic Multisite Group-Randomized Clinical Trial on Psychosocial Interventions in the Psychiatric and Addiction Field. Subst Abus. 2012;6:95.
    1. Grawe RW, Hagen R, Espeland B, Mueser KT. The better life program: effects of group skills training for persons with severe mental illness and substance use disorders. J Ment Health. 2007;16:625–634. doi: 10.1080/09638230701494886.
    1. Hotopf M. The pragmatic randomised controlled trial. Adv Psychiatr Treat. 2002;8:326–333. doi: 10.1192/apt.8.5.326.
    1. McLellan AT, Luborsky L, Woody GE, O’Brien CP. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis. 1980;168:26–33. doi: 10.1097/00005053-198001000-00006.
    1. Kokkevi A, Hartgers C. EuropASI: European Adaptation of a Multidimensional Assessment Instrument for Drug and Alcohol Dependence. Eur Addict Res. 1995;1:208–210. doi: 10.1159/000259089.
    1. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption–II. Addiction. 1993;88:791–804. doi: 10.1111/j.1360-0443.1993.tb02093.x.
    1. Berman AH, Bergman H, Palmstierna T, Schlyter F. Evaluation of the Drug Use Disorders Identification Test (DUDIT) in criminal justice and detoxification settings and in a Swedish population sample. Eur Addict Res. 2005;11:22–31. doi: 10.1159/000081413.
    1. Reinert DF, Allen JP. The alcohol use disorders identification test: an update of research findings. Alcohol Clin Exp Res. 2007;31:185–199. doi: 10.1111/j.1530-0277.2006.00295.x.
    1. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P) New York: Biometrics Research, New York State Psychiatric Institute; 2002.
    1. First MB, Gibbon M, Spitzer RL, Williams JBW, Benjamin LS. Structured Clinical Interview for DSM-IV Axis II Personality Disorders, (SCID-II) Washington, D.C: American Psychiatric Press, Inc; 1997.
    1. Derogatis LR, Cleary PA. Confirmation of Dimensional Structure of Scl-90 - Study in Construct-Validation. J Clin Psychol. 1977;33:981–989. doi: 10.1002/1097-4679(197710)33:4<981::AID-JCLP2270330412>;2-0.
    1. Derogatis LR, Cleary PA. Factorial invariance across gender for the primary symptom dimensions of the SCL-90. Br J Soc Clin Psychol. 1977;16:347–356. doi: 10.1111/j.2044-8260.1977.tb00241.x.
    1. Derogatis LR. The SCL-90 Manual I: Scoring, administration and procedures for the SCL-90. Baltimore: Johns Hopkins University School of Medicine, Clinical Psychometrics Unit; 1977.
    1. Wing JK, Beevor AS, Curtis RH, Park SB, Hadden S, Burns A. Health of the Nation Outcome Scales (HoNOS). Research and development. Br J Psychiatry. 1998;172:11–18. doi: 10.1192/bjp.172.1.11.
    1. Wing J, Curtis RH, Beevor A. Health of the Nation Outcome Scales (HoNOS) - Glossary for HoNOS score sheet. Br J Psychiatry. 1999;174:432–434. doi: 10.1192/bjp.174.5.432.
    1. Drake RE, Osher FC, Noordsy DL, Hurlbut SC, Teague GB, Beaudett MS. Diagnosis of alcohol use disorders in schizophrenia. Schizophr Bull. 1990;16:57–67. doi: 10.1093/schbul/16.1.57.
    1. Mueser KT, Drake RE, Clark RE, McHugo GJ, Mercer-McFadden C, Ackerson TH. Toolkit on evaluating substance abuse in persons with severe mental illness. Cambridge, MA: Human Services Research Institute; 1995.
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) Washington D.C.: American Psychiatric Association; 2000.
    1. Goldman HH, Skodol AE, Lave TR. Revising axis V for DSM-IV: a review of measures of social functioning. Am J Psychiatry. 1992;149:1148–1156.
    1. McHugo GJ, Drake RE, Burton HL, Ackerson TH. A scale for assessing the stage of substance abuse treatment in persons with severe mental illness. J Nerv Ment Dis. 1995;183:762–767. doi: 10.1097/00005053-199512000-00006.
    1. Connors GJ, Donovan DM, DiClemente CC. Substance Abuse Treatment and the Stages of Change. New York: Guilford Press; 2001.
    1. Prochaska JO. Systems of Psychotherapy: a transtheoretical analysis. Homewood, IL: Dorsey Press; 1984.
    1. Osher FC, Kofoed LL. Treatment of patients with psychiatric and psychoactive substance abuse disorders. Hosp Community Psychiatry. 1989;40:1025–1030.
    1. IBM Corp. IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp; 2011.
    1. Wüsthoff LE, Waal H, Gråwe RW. When Research Meets Reality- lessons Learned From a Pragmatic Multisite Group- Randomized Clinical Trial on Psychosocial Interventions in the Psychiatric and Addiction Field. Substance Abuse. 2012;6:95–106.
    1. Baker A, Turner A, Kay-Lambkin FJ, Lewin TJ. The long and the short of treatments for alcohol or cannabis misuse among people with severe mental disorders. Addict Behav. 2009;34:852–858. doi: 10.1016/j.addbeh.2009.02.002.
    1. Kypri K, Langley JD, Saunders JB, Cashell-Smith ML. Assessment may conceal therapeutic benefit: findings from a randomized controlled trial for hazardous drinking. Addiction. 2007;102:62–70. doi: 10.1111/j.1360-0443.2006.01632.x.
    1. Hesse M. Integrated psychological treatment for substance use and co-morbid anxiety or depression vs. treatment for substance use alone. A systematic review of the published literature. BMC Psychiatry. 2009;9:6. doi: 10.1186/1471-244X-9-6.
    1. Watkins KE, Hunter S, Hepner K, Paddock S, Zhou A, de la Cruz E. Group cognitive-behavioral therapy for clients with major depression in residential substance abuse treatment. Psychiatr Serv. 2012;63:608–611.
    1. Baker AL, Kavanagh DJ, Kay-Lambkin FJ, Hunt SA, Lewin TJ, Carr VJ, Connolly J. Randomized controlled trial of cognitive-behavioural therapy for coexisting depression and alcohol problems: short-term outcome. Addiction. 2010;105:87–99. doi: 10.1111/j.1360-0443.2009.02757.x.
    1. Miller WR. Motivational interviewing: research, practice, and puzzles. Addict Behav. 1996;21:835–842. doi: 10.1016/0306-4603(96)00044-5.
    1. Saunders B, Wilkinson C, Phillips M. The impact of a brief motivational intervention with opiate users attending a methadone programme. Addiction. 1995;90:415–424. doi: 10.1111/j.1360-0443.1995.tb03788.x.
    1. English R, Lebovitz Y, Griffin R. Transforming Clinical Research in the United States: Challenges and Opportunities: Workshop Summary. Washington, D.C: National Academies Press, Institute of medicine of the National Academies; 2010. (Forum on Drug Discovery, Development, and Translation Board on Health Sciences Policy).
    1. Rendell JM, Licht RW. Under-recruitment of patients for clinical trials: an illustrative example of a failed study. Acta Psychiatr Scand. 2007;115:337–339. doi: 10.1111/j.1600-0447.2007.01019.x.
    1. Lehman AF, Herron JD, Schwartz RP, Myers CP. Rehabilitation for adults with severe mental illness and substance use disorders. A clinical trial. J Nerv Ment Dis. 1993;181:86–90. doi: 10.1097/00005053-199302000-00003.
    1. Burnam MA, Morton SC, McGlynn EA, Petersen LP, Stecher BM, Hayes C, Vaccaro JV. An experimental evaluation of residential and nonresidential treatment for dually diagnosed homeless adults. J Addict Dis. 1995;14:111–134.
    1. Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients’ care. Lancet. 2003;362:1225–1230. doi: 10.1016/S0140-6736(03)14546-1.
    1. Hannes K, Pieters G, Goedhuys J, Aertgeerts B. Exploring barriers to the implementation of evidence-based practice in psychiatry to inform health policy: a focus group based study. Community Ment Health J. 2010;46:423–432. doi: 10.1007/s10597-009-9260-1.
    1. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;357:1191–1194. doi: 10.1016/S0140-6736(00)04337-3.
    1. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gotzsche PC, Lang T. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134:663–694. doi: 10.7326/0003-4819-134-8-200104170-00012.
    1. Campbell MK, Elbourne DR, Altman DG. CONSORT statement: extension to cluster randomised trials. BMJ. 2004;328:702–708. doi: 10.1136/bmj.328.7441.702.
    1. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P. Methods and processes of the CONSORT Group: example of an extension for trials assessing nonpharmacologic treatments. Ann Intern Med. 2008;148:W60–W66.
    1. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med. 2010;7:e1000251. doi: 10.1371/journal.pmed.1000251.
    1. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010;63:e1–e37. doi: 10.1016/j.jclinepi.2010.03.004.
    1. Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371:281–283. doi: 10.1016/S0140-6736(07)61835-2.
    1. Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008;5:e20. doi: 10.1371/journal.pmed.0050020.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다